Viennese Covid-19 vaccine candidate to score long-term

0 0
Read Time:1 Minute, 11 Second

In the race for Covid-19 vaccines, the biotech company Valneva, which maintains a large research site in Vienna, chose a special path. Behind the candidate name “VLA2001” is a vaccine containing inactivated viruses.

With inactivated vaccines, the body is confronted with harmless viruses. As a result, the body’s own defense system deals with the pathogen and develops the necessary protective immune response. This approach has been tried and tested for many decades. “We knew from the beginning that we would be late with this approach because it takes longer to develop”, he says. “It also takes longer to set up large-scale production than is the case with some vaccines with novel approaches that are now on the horizon.”

However, the tried-and-tested technology can guarantee a high level of safety. Since the body gets the entire killed virus presented, the immune system must fight with all pathogen parts, which can be expected after a revitalization inoculation a longer lasting immunization of five to ten years, showed up Lingelbach convinced. Moreover, it can be expected that “special target groups” such as small children, persons with an attacked immune system or pregnant women can be vaccinated without hesitation. These advantages could then be strongly reflected in the second wave of vaccines. Up to 20 percent of the population in Austria are considered potential recipients of the vaccine.

  • hp, source:derstandard.at. picture: pixabay.com
Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

This post has already been read 257 times!

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *